17,261 trials
Degenerative Disc Disease · Intervertebral Disc Disease · Low Back Pain
Primary: Pain and Disability Evaluation — 0.28; 0.15 scores from 0 to 1
Melanoma
Primary: Safety and Tolerability of the Combination of IMM-101 + Nivolumab — 16; 14; 6; 14 Participants
Stage IIIC Cutaneous Melanoma AJCC v7 · Stage IV Cutaneous Melanoma AJCC v6 and v7 · Unresectable Melanoma
Primary: Overall Survival (OS) — 20.4; 20.1 months — p=0.383
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Objective Response Rate (Complete Response/Partial Response) — 0 percentage of participants
Neuroblastoma Recurrent
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 2; 1; 3 Participants
Solid Tumors · Cancer
Primary: Objective Response Rate (ORR) - LEAD IN STAGE, RDT Cohorts and NRE Ovarian Cohort Only — 4.7; 5.2; 10; 0 percentage of participants
PH1 · Primary Hyperoxaluria · RNAi Therapeutic
Primary: Number of Participants With at Least One Adverse Event (AE) — 13; 7 Participants
Advanced Malignant Solid Neoplasm · Recurrent Childhood Ependymoma · Recurrent Ewing Sarcoma
Primary: Objective Response Rate — 0 percentage of participants
Duchenne Muscular Dystrophy
Primary: Number of Participants Experiencing Acute Respiratory Decompensation — 0; 0 Participants
Meibomian Gland Dysfunction
Primary: IOP of Study Eye Related to Safety — 16.547; 16.328; 16.241 mmHg
Meibomian Gland Dysfunction
Primary: IOP Related to Safety — 15.906; 16.452; 16.469 mmHg
Primary Biliary Cholangitis · Primary Biliary Cirrhosis · Cholangitis
Primary: Percent Change in Alkaline Phosphatase (ALP) at Week 12 Compared to Baseline — -7.7 percent change — p==0.077
Dyslipidemias · High Cholesterol · Hypercholesterolemia
Primary: Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]…
Papulopustular Rosacea
Primary: Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions — -10.0; -6.7; -9.2 lesions (rosacea inflammatory)
Bone Marrow Transplantation Recipient · Cord Blood Transplant Recipient · Hematopoietic Cell Transplantation Recipient
Primary: Number of Participants That Achieved Platelet Engraftment Greater Than 50K/ul — 3; 30 Participants